Stemline Therapeutics (STML) Misses Q4 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. TMUS
7. SPY
8. CVS
9. UNH
10. DAL

Go back to Stemline Therapeutics (STML) Misses Q4 EPS by 2c

Stemline Therapeutics (STML) PT Trimmed at Wedbush; Shares Remain Undervalued

March 17, 2015 12:23 PM EDT

Wedbush analyst David Nierengarten reiterated an Outperform rating on Stemline Therapeutics (NASDAQ: STML) but trimmed his price target to $35.00 (from $49.00) after the company reported a smaller-than-expected Q4 loss. The target cut comes as they push out their launch timeline. However, they still view the stock... More